iSpecimen Inc. (ISPC)
USD 1.25
(-2.34%)
USD 1.25
(-2.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -9.1 Million USD | 9.03% |
| 2022 | -8.8 Million USD | -67.95% |
| 2021 | -5.85 Million USD | -277.93% |
| 2020 | -1.73 Million USD | 48.74% |
| 2019 | -2.52 Million USD | -8.15% |
| 2018 | -3.78 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.57 Million USD | 34.91% |
| 2024 Q1 | -2.4 Million USD | 9.1% |
| 2023 Q4 | -2.33 Million USD | -10.78% |
| 2023 FY | - USD | 9.03% |
| 2023 Q3 | -2.1 Million USD | 28.38% |
| 2023 Q2 | -2.94 Million USD | -21.13% |
| 2023 Q1 | -2.42 Million USD | -17.9% |
| 2022 Q2 | -2.29 Million USD | -10.53% |
| 2022 Q1 | -2.07 Million USD | -3.21% |
| 2022 Q3 | -2.73 Million USD | -19.48% |
| 2022 FY | - USD | -67.95% |
| 2022 Q4 | -2.05 Million USD | 24.83% |
| 2021 Q2 | -1.27 Million USD | -82.47% |
| 2021 FY | - USD | -277.93% |
| 2021 Q1 | -699.97 Thousand USD | 6.01% |
| 2021 Q4 | -2.01 Million USD | -64.36% |
| 2021 Q3 | -1.22 Million USD | 4.24% |
| 2020 Q4 | -744.74 Thousand USD | -38.22% |
| 2020 FY | - USD | 48.74% |
| 2020 Q3 | -538.79 Thousand USD | -668.14% |
| 2020 Q2 | -70.14 Thousand USD | 68.75% |
| 2020 Q1 | -224.46 Thousand USD | 58.46% |
| 2019 FY | - USD | -8.15% |
| 2019 Q3 | -1.53 Million USD | 0.0% |
| 2019 Q4 | -540.32 Thousand USD | 64.74% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 92.256% |
| Biodesix, Inc. | -37.1 Million USD | 75.464% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -19.326% |
| Castle Biosciences, Inc. | -45.02 Million USD | 79.78% |
| DarioHealth Corp. | -53.49 Million USD | 82.982% |
| Exact Sciences Corporation | 41.87 Million USD | 121.74% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 100.748% |
| Illumina, Inc. | -608 Million USD | 98.503% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -3.326% |
| Standard BioTools Inc. | -54.45 Million USD | 83.283% |
| 23andMe Holding Co. | -291.87 Million USD | 96.881% |
| Medpace Holdings, Inc. | 363.15 Million USD | 102.507% |
| NeoGenomics, Inc. | -17.6 Million USD | 48.295% |
| Inotiv, Inc. | -26.5 Million USD | 65.654% |
| Psychemedics Corporation | -251 Thousand USD | -3526.98% |
| Prenetics Global Limited | -47.89 Million USD | 80.993% |
| Precipio, Inc. | -4.31 Million USD | -110.832% |
| RadNet, Inc. | 292.78 Million USD | 103.109% |
| Sotera Health Company | 514.14 Million USD | 101.771% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -439.64% |
| Exagen Inc. | -19.15 Million USD | 52.468% |
| Natera, Inc. | -383.27 Million USD | 97.625% |
| Aspira Women's Health Inc. | -16.49 Million USD | 44.796% |
| Neogen Corporation | 182.59 Million USD | 104.986% |
| Myriad Genetics, Inc. | -67.8 Million USD | 86.573% |
| ICON Public Limited Company | 1.63 Billion USD | 100.558% |
| Bionano Genomics, Inc. | -213.6 Million USD | 95.738% |
| CareDx, Inc | -89.65 Million USD | 89.846% |
| Check-Cap Ltd. | -17.64 Million USD | 48.418% |
| Twist Bioscience Corporation | -176.7 Million USD | 94.848% |
| Guardant Health, Inc. | -433.3 Million USD | 97.899% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -266.323% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 80.444% |
| Sera Prognostics, Inc. | -35.28 Million USD | 74.201% |
| OPKO Health, Inc. | -65.51 Million USD | 86.105% |
| Personalis, Inc. | -96.8 Million USD | 90.596% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | 5.081% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -439.64% |
| MDxHealth SA | -30.46 Million USD | 70.12% |
| Prenetics Global Limited | -47.89 Million USD | 80.993% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 6.961% |
| Mainz Biomed B.V. | -25.01 Million USD | 63.601% |
| Trinity Biotech plc | -24.09 Million USD | 62.222% |
| Neuronetics, Inc. | -22.75 Million USD | 59.999% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -19.326% |